According to BMS’ latest annual report, the company has set an estimated minimum market entry date for U.S. Opdivo copycats in 2028. (Getty Images) As Amgen advances its bid to join the first wave of ...

To establish an operational presence in the U.S., reinsurance broker Willis Re on Aug. 18 said it is acquiring BMS Re, US. The deal includes BMS Intermediaries Inc. and BMS Capital Advisory LLC, as ...

Willis Re, the reinsurance business of Willis Towers Watson, said Tuesday it has agreed to acquire the U.S. division of BMS Re, the reinsurance brokerage arm of London-based BMS Group, in a deal that ...

CEO Chris Boerner, Ph.D., suggested he would be tempted by an asset in “therapeutic areas that we know well.” (Bristol Myers Squibb) Bristol Myers Squibb may have been noticeable by its absence from ...

It’s officially a trend. For the third time in nine months, a pharma company has announced that it is assembling the largest AI supercomputer in the life sciences industry. This time, it is Bristol ...

Nintendo will shut down smartphone racer Mario Kart Tour this September, after seven years of service. A notice posted on social media this morning revealed that the iPhone and Android game will cease ...

All 22 drivers drove go-karts featuring 28,000 Lego bricks. Clive Rose/Getty Images Formula 1’s second edition of its Lego drivers’ parade, this time using go-karts featuring 28,000 Lego bricks, ended ...

BMS' first-quarter revenues climbed 3% to $11.5 billion, with $6.2 billion of the haul coming from its newer growth product portfolio. (Angus Liu/Fierce Pharma) Bristol Myers Squibb’s growth portfolio ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

That’s the declaration belted by Mario in his chintziest Italian accent at the start screen of 1996’s Mario Kart 64. It’s a cry most Millennials recall fondly, and for good reason. It’s a welcome to ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...